481 related articles for article (PubMed ID: 28687616)
1. Posttranscriptional Regulation of
Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
[TBL] [Abstract][Full Text] [Related]
2. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
[TBL] [Abstract][Full Text] [Related]
3. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.
Lukosiute-Urboniene A; Jasukaitiene A; Silkuniene G; Barauskas V; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2019 Jan; 25(2):205-219. PubMed ID: 30670910
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.
Jain A; Agostini LC; McCarthy GA; Chand SN; Ramirez A; Nevler A; Cozzitorto J; Schultz CW; Lowder CY; Smith KM; Waddell ID; Raitses-Gurevich M; Stossel C; Gorman YG; Atias D; Yeo CJ; Winter JM; Olive KP; Golan T; Pishvaian MJ; Ogilvie D; James DI; Jordan AM; Brody JR
Cancer Res; 2019 Sep; 79(17):4491-4502. PubMed ID: 31273064
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
6. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.
Jimbo M; Blanco FF; Huang YH; Telonis AG; Screnci BA; Cosma GL; Alexeev V; Gonye GE; Yeo CJ; Sawicki JA; Winter JM; Brody JR
Oncotarget; 2015 Sep; 6(29):27312-31. PubMed ID: 26314962
[TBL] [Abstract][Full Text] [Related]
7. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
[TBL] [Abstract][Full Text] [Related]
8. Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain.
Poitras MF; Koh DW; Yu SW; Andrabi SA; Mandir AS; Poirier GG; Dawson VL; Dawson TM
Neuroscience; 2007 Aug; 148(1):198-211. PubMed ID: 17640816
[TBL] [Abstract][Full Text] [Related]
9. PARG Inhibitors and Functional PARG Inhibition Models.
Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
[TBL] [Abstract][Full Text] [Related]
10. Altered poly(ADP-ribose) metabolism impairs cellular responses to genotoxic stress in a hypomorphic mutant of poly(ADP-ribose) glycohydrolase.
Gao H; Coyle DL; Meyer-Ficca ML; Meyer RG; Jacobson EL; Wang ZQ; Jacobson MK
Exp Cell Res; 2007 Mar; 313(5):984-96. PubMed ID: 17276427
[TBL] [Abstract][Full Text] [Related]
11. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.
Zarei M; Lal S; Parker SJ; Nevler A; Vaziri-Gohar A; Dukleska K; Mambelli-Lisboa NC; Moffat C; Blanco FF; Chand SN; Jimbo M; Cozzitorto JA; Jiang W; Yeo CJ; Londin ER; Seifert EL; Metallo CM; Brody JR; Winter JM
Cancer Res; 2017 Aug; 77(16):4460-4471. PubMed ID: 28652247
[TBL] [Abstract][Full Text] [Related]
12. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis.
Min W; Cortes U; Herceg Z; Tong WM; Wang ZQ
Carcinogenesis; 2010 Dec; 31(12):2058-65. PubMed ID: 20926829
[TBL] [Abstract][Full Text] [Related]
13. Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer.
Tanuma SI; Shibui Y; Oyama T; Uchiumi F; Abe H
Biochem Pharmacol; 2019 Sep; 167():163-172. PubMed ID: 31176615
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribosyl)ation enhances HuR oligomerization and contributes to pro-inflammatory gene mRNA stabilization.
Ke Y; Lv X; Fu X; Zhang J; Bohio AA; Zeng X; Hao W; Wang R; Boldogh I; Ba X
Cell Mol Life Sci; 2021 Feb; 78(4):1817-1835. PubMed ID: 32789690
[TBL] [Abstract][Full Text] [Related]
15. Silencing of the mRNA-binding protein HuR increases the sensitivity of colorectal cancer cells to ionizing radiation through upregulation of caspase-2.
Badawi A; Hehlgans S; Pfeilschifter J; Rödel F; Eberhardt W
Cancer Lett; 2017 May; 393():103-112. PubMed ID: 28219770
[TBL] [Abstract][Full Text] [Related]
16. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
17. Disrupted ADP-ribose metabolism with nuclear Poly (ADP-ribose) accumulation leads to different cell death pathways in presence of hydrogen peroxide in procyclic Trypanosoma brucei.
Schlesinger M; Vilchez Larrea SC; Haikarainen T; Narwal M; Venkannagari H; Flawiá MM; Lehtiö L; Fernández Villamil SH
Parasit Vectors; 2016 Mar; 9():173. PubMed ID: 27007296
[TBL] [Abstract][Full Text] [Related]
18. An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells.
Dong R; Chen P; Polireddy K; Wu X; Wang T; Ramesh R; Dixon DA; Xu L; Aubé J; Chen Q
Mol Cancer Ther; 2020 Nov; 19(11):2267-2277. PubMed ID: 32879054
[TBL] [Abstract][Full Text] [Related]
19. CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype.
Lal S; Cheung EC; Zarei M; Preet R; Chand SN; Mambelli-Lisboa NC; Romeo C; Stout MC; Londin E; Goetz A; Lowder CY; Nevler A; Yeo CJ; Campbell PM; Winter JM; Dixon DA; Brody JR
Mol Cancer Res; 2017 Jun; 15(6):696-707. PubMed ID: 28242812
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
